MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on August 3, 2005; DOI: 10.1124/mol.105.011478

0026-895X/05/6805-1225-1238$20.00
Mol Pharmacol 68:1225-1238, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.105.011478v1
68/5/1225    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helvering, L. M.
Right arrow Articles by Onyia, J. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helvering, L. M.
Right arrow Articles by Onyia, J. E.

Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene

Leah M. Helvering, Riting Liu, Nalini H. Kulkarni, Tao Wei, Peining Chen, Shuguang Huang, Frank Lawrence, David L. Halladay, Rebecca R. Miles, Emily M. Ambrose, Masahiko Sato, Yanfei L. Ma, Charles A. Frolik, Ernst R. Dow, Henry U. Bryant, and Jude E. Onyia

Lilly Research Labs, Indianapolis, Indiana (L.M.H., N.H.K., T.W., P.C., S.H., F.L., D.L.H., R.R.M., E.M.A., M.S., Y.L.M., C.A.F., E.R.D., H.U.B., J.E.O.); and MBA Program/Innovation Realization Lab, Krannert School of Management, Purdue University, West Lafayette, Indiana (R.L.)

The pharmacological preservation of bone in the ovariectomized rat by estrogen, selective estrogen receptor modulators (SERMs), and bisphosphonates has been well described. However, comprehensive molecular analysis of the effects of these pharmacologically diverse antiresorptive agents on gene expression in bone has not been performed. This study used DNA microarrays to analyze RNA from the proximal femur metaphysis of sham and ovariectomized vehicle-treated rats, and ovariectomized rats treated for 35 days with maximally efficacious doses of 17-{alpha} ethinyl estradiol, the benzothiophene SERM, raloxifene, the benzopyran SERM, (S)-3-(4-hydroxyphenyl)-4-methyl-2-[4-[2-(1-piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-7-ol (EM652), and the aminobisphosphonate, alendronate. Ovariectomy resulted in 644 significant probe set changes relative to sham control rats (p < 0.05), whereas E2, raloxifene, EM652, and alendronate regulated 613, 765, 652, and 737 probe sets, respectively, relative to ovariectomized control rats. An intersection of these data sets yielded 334 unique genes that were altered after ovariectomy and additionally changed by one or more antiresorptive treatment. Clustering analysis showed that the transcript profile was distinctly different for each pharmaceutical agent and that raloxifene maintained more genes at sham levels than any other treatment. In addition, E2 and alendronate suppressed a cluster of genes associated with bone formation activity below that of sham, whereas raloxifene had little effect on these genes. These data indicate stronger suppressive effects of E2 and alendronate on bone formation activity and that ovariectomy plus raloxifene resembles sham more closely than ovariectomized animals treated with E2, EM652, or alendronate.

Received February 11, 2005; accepted August 1, 2005

Address correspondence to: L. M. Helvering, Endocrine Research Division, Lilly Research Labs, Indianapolis, IN 46285, E-mail: l.helvering{at}lilly.com






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics